Merck & Company (MRK) Received its Third Buy in a Row

After Guggenheim and Credit Suisse gave Merck & Company (NYSE: MRK) a Buy rating last month, the company received another Buy, this time from Barclays. Analyst Geoff Meacham maintained a Buy rating on Merck & Company today and set a price target of $78. The company’s shares closed yesterday at $68.37.

According to, Meacham is a 4-star analyst with an average return of 4.8% and a 53.5% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Alexion Pharmaceuticals, and United Therapeutics.

Merck & Company has an analyst consensus of Strong Buy, with a price target consensus of $74.71, a 9.3% upside from current levels. In a report issued on October 8, Guggenheim also initiated coverage with a Buy rating on the stock with a $84 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $72.89 and a one-year low of $52.83. Currently, Merck & Company has an average volume of 8M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

From Our Partners